Dernières publications scientifiques

  • First genome-wide association study reveals immune-mediated aetiopathology in idiopathic achalasia.

  • Auteurs Grover S, Gockel I, Latiano A, Mokrowiecka A, Dasmeh P, Wouters MM, Vackova Z, Haas SL, Triantafyllou T, Kreuser N, Trautmann J, Niebisch S, Hess T, Thieme R, Bigge J, Louis H, Quertinmont E, Meirhaeghe A, Muntaner M, Amouyel P, Gourcerol G, Bruley des Varannes S, Mion F, Vieth M, Scarmeas N, Palmieri O, Tavano F, De Giorgio R, Galimberti D, Arighi A, Arosio B, Bruno M, Wasielica-Berger J, Gawron-Kiszka M, Janiak M, Siepsiak M, Adrych K, Marek T, Dabrowski A, Majewski M, Gietka P, Gonciarz M, Pérez de la Serna J, Martínez LZ, Giedraitis V, Kilander L, Fratiglioni L, Real LM, Spicak J, Tack J, Heilmann-Heimbach S, Nöthen M, Ingelsson M, Graff C, Ruiz A, Lambert JC, Ramirez A, Eckardt AJ, Müller M, Knapp M, Wissinowski TT, Keller J, Bruns CJ, Gerges C, Neuhaus H, Rösch T, Siegmund B, Schumacher B, Venerito M, Ruiz de León A, Rosati R, Annese V, Fumagalli U, Laghi L, Urcelay E, Vavasseur F, Roman S, Zhou P, Li Q, Liu Z, Rahden BHAV, Theodorou D, Malecka-Panas E, Maj C, Vigo AG, Martinek J, Boeckxstaens G, Schumacher J
  • Auteurs (entité) Louis Hubert
  • Revue Gut
  • Date de publication 2025-10
First genome-wide association study reveals immune-mediated aetiopathology in idiopathic achalasia.
  • EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer.

  • Auteurs Menis J, Greiller L, Demontrond P, Monnet I, Novello S, Livi L, Young R, Decroisette C, Cloarec N, Robinet G, Schott R, Fayette J, Banna GL, De Marinis F, Califano R, Duchemann B, Luciani A, Colantonio I, Fournier B, Pretzenbacher Y, Caramella C, Silva M, Berghmans T, Dingemans AM, Bironzo P, Tugwood J, Zhou C, Hill S, Bradbury K, Morris K, Kilgour E, Dive C, Blackhall F, Besse B
  • Auteurs (entité) BERGHMANS THIERRY
  • Revue Eur J Cancer
  • Date de publication 2025-10
EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer.
  • 35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.

  • Auteurs Moreau P, Hulin C, Talbot A, Demarquette H, Caillot L, Chalopin T, Bobin A, Manier S, Leleu X, Karlin L, Caillot D, Sonntag C, Feugier P, Roussel M, Gounot R, Macro M, Mohty M, Garderet L, Tiab M, Orsini-Piocelle F, Vincent L, Meuleman N, Fontan J, Montes L, Vekemans MC, Escoffre-Barbe M, Eveillard JR, Schiano de Colella JM, Lambert J, Mary JY, Fermand JP, Arnulf B, Corre J, Avet-Loiseau H, Facon T, Harousseau JL, Touzeau C, Perrot A
  • Auteurs (entité) MEULEMAN NATHALIE
  • Revue Blood Cancer J
  • Date de publication 2025-10
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.
  • AI-assisted basal cell carcinoma diagnosis with LC-OCT: A multicentric retrospective study.

  • Auteurs Fischman S, Viel T, Perrot JL, Pérez-Anker J, Suppa M, Cinotti E, Lenoir C, Orte Cano C, Welzel J, Schuh S, Sattler EC, Del Marmol V, Rubegni P, Dragotto M, Cioppa V, Falcinelli F, Cappilli S, Challe S, Tavernier C, Malvehy J, Tognetti L
  • Auteurs (entité) Del Marmol Veronique
  • Revue J Eur Acad Dermatol Venereol
  • Date de publication 2025-10
AI-assisted basal cell carcinoma diagnosis with LC-OCT: A multicentric retrospective study.
  • RSC4All as a machine learning nomogram to predict RSClin™ results in HR+/HER2- node-negative early breast cancer.

  • Auteurs Jacobs F, D'Amico S, Ferraro E, Agostinetto E, Tondini C, Gaudio M, Benvenuti C, Gerosa R, Saltalamacchia G, Zazzetti E, Di Rienzo R, Buonaiuto R, Martorana F, Chirco A, De Sanctis R, Della Porta MG, Santoro A, Vigneri P, Arpino MG, Giuliano M, Fornier M, de Azambuja E, Zambelli A
  • Auteurs (entité) AGOSTINETTO ELISA
  • Revue ESMO Open
  • Date de publication 2025-10
RSC4All as a machine learning nomogram to predict RSClin™ results in HR+/HER2- node-negative early breast cancer.
  • Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group.

  • Auteurs Brandão M, Prisciandaro E, Xenophontos E, Mariolo A, Sadeghi AH, Filippi AR, Levy A, Bandura A, Caramella C, Dickhoff C, de Margerie-Mellon C, Faivre-Finn C, Portik D, Sanchez-Lorente D, De Ruysscher D, Smit E, Gobbini E, Fadel E, Ruffini E, Olmetto E, Cortiula F, Bahce I, Houda I, Opitz I, Naidoo J, Edwards J, Remon J, Benitez JC, Trujillo JC, Derks J, Amrane K, Hartemink KJ, Stathopoulos K, Hendriks LEL, Iglesias M, Occhipinti M, Guckenberger M, Giaj Levra N, Girard N, Reguart N, Mercier O, Bironzo P, Hofman P, Petersen RH, De Angelis R, Abgral R, Terrisse S, Popat S, Pierret T, Blum TG, Ricardi U, Dionisi V, Berghmans T, Dingemans AC
  • Auteurs (entité) BERGHMANS THIERRY
  • Revue Lung Cancer
  • Date de publication 2025-10
Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group.
  • Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer.

  • Auteurs Lei M, Overman MJ, Yao J, André T, Lonardi S, Lenz HJ, Aglietta M, Gelsomino F, McDermott R, Wong KYM, Morse MA, Van Cutsem E, Hendlisz A, Cardin DB, Neyns B, Hill A, Krishnamurthy A, Chen F, Kochuparambil S, Jenq RR, Abdullaev S, He B, Novosiadly R, Kopetz S
  • Auteurs (entité) HENDLISZ ALAIN
  • Revue Nat Commun
  • Date de publication 2025-10
Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer.
Bordet hospital

Institut Jules Bordet

Consultez toutes les publications scientifiques de Jules Bordet

Erasme hospital

Hôpital Erasme

Consultez toutes les publications scientifiques d'Erasme

Huderf hospital

Hôpital pédiatrique Reine Fabiola

Voir toutes les publications scientifiques de l'Hôpital pédiatrique Reine Fabiola